中国药物警戒 ›› 2019, Vol. 16 ›› Issue (1): 47-51.

• 安全性评价与合理用药 • 上一篇    下一篇

斑蝥不良反应文献分析

于洪礼1, 于冬梅2   

  1. 1国家药品监督管理局药品评价中心,北京 100045;
    2国家药品监督管理局保健食品审评中心,北京 100070
  • 收稿日期:2018-09-18 修回日期:2019-02-18 出版日期:2019-01-20 发布日期:2019-02-18
  • 作者简介:于洪礼,男,硕士,主管药师,中药学。
  • 基金资助:
    国家科技重大专项(2015ZX09501004-001-001):基于SRS系统的动态、长效中药风险信号早期发现研究

Literature Review of Adverse Drug Reactions Induced by Mylabris

YU Hongli1, YU Dongmei2   

  1. 1Center for Drug Reevaluation, NMPA, Beijing 100045, China;
    2Center for Health Food Review, NMPA, Beijing 100070, China
  • Received:2018-09-18 Revised:2019-02-18 Online:2019-01-20 Published:2019-02-18

摘要: 目的 研究斑蝥的不良反应发生规律和特点,以期为安全合理使用斑蝥提供参考。方法 检索斑蝥相关的不良反应文献,分析斑蝥的不良反应特点及风险因素。结果 纳入文献84篇,病例报告112例。斑蝥的不良反应涉及人体多个系统-器官。引发不良反应的主要原因是毒性反应和不合理用药。结论 加强监管对斑蝥的安全合理用药具有重要意义。

关键词: 斑蝥, 不良反应, 文献

Abstract: Objective To investigate the general characteristics of adverse drug reactions (ADRs) induced by Mylabris (Banmao), so as to provide reference for safe and rational drug use. Methods The cases of ADRs induced by Mylabris were retrieved, and the characteristics of ADRs and risk factors were analyzed. Results The total of 112 cases of ADRs were included in 84 literature reports. According to the analysis, the ADRs involved multiple organs and systems. The main causes were toxicity reactions and irrational drug use. Conclusion It is necessary to strengthen regulation to guidance for the safe and rational use of Mylabris.

Key words: Mylabris, adverse reaction, literature

中图分类号: